Biocon launches Tacrolimus capsules in US
Capital MarketBiocon announced the launch of Tacrolimus capsules in the US. Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ
transplant patients, which reduces the body's ability to reject a transplanted organ. It has been
particularly effective in treating patients of renal transplant for more than two decades.
The launch of Tacrolimus capsules, following an approval from the US FDA in November 2020.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
